<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759248</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1907</org_study_id>
    <secondary_id>2020-000245-13</secondary_id>
    <nct_id>NCT04759248</nct_id>
  </id_info>
  <brief_title>Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer</brief_title>
  <acronym>ATREZZO</acronym>
  <official_title>A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors given in monotherapy in advanced breast cancer have shown modest&#xD;
      benefit in first-line, but very limited efficacy in later lines. Thus, combination therapies&#xD;
      are needed.&#xD;
&#xD;
      Response following anti-PD1/PD-L1 monotherapy is associated with large survival benefit in&#xD;
      the advanced setting.&#xD;
&#xD;
      Previous studies of the intrinsic subtypes have shown that Basal-like and HER2-E are&#xD;
      associated with higher expression of immune-related genes or higher infiltration of stromal&#xD;
      tumor infiltrating lymphocytes compared to the luminal subtypes. Immune infiltration in BC is&#xD;
      associated with chemo/antiHER2 responsiveness and potentially benefit from anti-PD-1/PD-L1&#xD;
      inhibitors.&#xD;
&#xD;
      In addition, one emerging biomarker of response to anti-PD-1 therapy is the tumor mutational&#xD;
      burden (I.e. the total number of mutations per coding area of a tumor genome). The HER2-E and&#xD;
      Basal-like profiles have been associated with high mutational burden.&#xD;
&#xD;
      A range of studies have been initiated including several phase II/III studies evaluating&#xD;
      atezolizumab in combination with different chemotherapeutic compounds routinely used in&#xD;
      breast cancer, but none with predefined biomarker beyond the expression of PD-L1 by IHC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">February 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, single arm, Simon 2-stage, multicenter phase II with 2 cohorts study evaluating treatment with atezolizumab in combination with trastuzumab and vinorelbine in patients with locally advanced or metastatic PAM50 non-luminal/HER2+ BC refractory to Trastuzumab/Pertuzumab based therapy and T-DM1.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response rate in PD-L1+ patients</measure>
    <time_frame>until disease progression or up to 2 years after treatment ends</time_frame>
    <description>the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate in PD-L1-neg patients</measure>
    <time_frame>until disease progression or up to 2 years after treatment ends</time_frame>
    <description>the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical Benefit Rate at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overal survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>survival at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>Survival witouth observed progression at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 weeks</time_frame>
    <description>time from first documented response until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>24 weeks</time_frame>
    <description>time until first documented response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>until end of treatment / through study completion, an average of 1 year</time_frame>
    <description>AEs according to CTCAE v 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab in combination with Trastuzumab and Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab + Trastuzumab + Vinorelbine</intervention_name>
    <description>Atezolizumab IV 1200 mg in combination with&#xD;
Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and&#xD;
Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV.</description>
    <arm_group_label>Atezolizumab in combination with Trastuzumab and Vinorelbine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (Premenopausal or postmenopausal women)&#xD;
&#xD;
          -  ECOG 0 to 2&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast, metastatic or unresectable&#xD;
             locally advanced.&#xD;
&#xD;
          -  All patients must have received at least pertuzumab/trastuzumab and T-DM1&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 criteria.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Baseline LVEF ≥50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational anticancer drug within 14 days of the start of&#xD;
             study treatment.&#xD;
&#xD;
          -  Patient has received Vinorelbine or any other vinca alkaloids previously.&#xD;
&#xD;
          -  History of other malignant tumors in the past 3 years&#xD;
&#xD;
          -  Symptomatic hypercalcemia requiring treatment with bisphosphonates in the 14 days&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Cardiopulmonary dysfunction&#xD;
&#xD;
          -  Any other severe, uncontrolled&#xD;
&#xD;
          -  Major surgery in the 28 days prior to enrolment&#xD;
&#xD;
          -  Infection with HIV or active Hepatitis B and/or Hepatitis C.&#xD;
&#xD;
          -  History of trastuzumab intolerance, including grade 3-4 infusion reaction or&#xD;
             hypersensitivity.&#xD;
&#xD;
          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab formulation&#xD;
&#xD;
          -  History of autoimmune disease,&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing&#xD;
             pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or&#xD;
             evidence of active pneumonitis on screening chest CT scan. (Note: History of radiation&#xD;
             pneumonitis in the radiation field [fibrosis] is permitted.)&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Receipt of a live, attenuated vaccine within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or&#xD;
             immune checkpoint targeting agents&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
             interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug prior&#xD;
             to enrolment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to&#xD;
             enrolment, or anticipated requirement for systemic immunosuppressive medications&#xD;
             during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H. Clínico San Cecilio de Granada</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabel Blancas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sonia Pernas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Josefina Cruz Jurado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comp. Hosp.Univ. Santiago (Chus)</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>La Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria E Perez López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Juan Ponce Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olga Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Santiago Escrivá, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago Gonzalez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen García</last_name>
      <phone>(+34) 93 274 60 00 ext 4911</phone>
      <email>cmgarciah.imas12@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Eva Ciruelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>_Ursula Sastre</last_name>
      <phone>+34 871 20 61 30</phone>
      <email>ursula.sastre@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Antonia Perelló, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cinta Albacar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Javier Salvador Bonfill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Miguel Cejalvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

